TCM
EW icon

Tuttle Capital Management’s Edwards Lifesciences EW Stock Holding History

Tuttle Capital Management’s Portfolio EW Stock Details EW Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q2 		– Sell
-31,230
Closed -$1.96M – 126
2020
Q1 		$1.96M Buy
31,230
+11,241
+56% +$811K 1.05% 20
2019
Q4 		$1.55M Buy
+19,989
New +$1.56M 0.59% 42
2019
Q2 		– Sell
-36,918
Closed -$2.35M – 119
2019
Q1 		$2.35M Buy
+36,918
New +$2.11M 0.47% 67

Other funds holding EW

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return
Sands Capital Management
Sands Capital Management Arlington, Virginia $25.5B AUM 26.46% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Brown Advisory
Brown Advisory Baltimore, Maryland $60.9B AUM 15.24% 1-Year Est. Return

Tuttle Capital Management's EW Position: Q2 2020 in Review

Tuttle Capital Management sold out of Edwards Lifesciences (EW) in Q2 2020, closing a stake of 31,230 shares — an estimated $1.96M sold.

Tuttle Capital Management first reported a position in EW in Q1 2019 and held it in 3 quarters. The position peaked at $2.35M in Q1 2019. 1,047 funds tracked by Wall St. Rank hold EW as of Q2 2020.

  • Tuttle Capital Management reported no remaining Edwards Lifesciences position as of Q2 2020 after selling out during the quarter.
  • Tuttle Capital Management sold 31,230 Edwards Lifesciences shares in Q2 2020, an estimated $1.96M.
  • Tuttle Capital Management first reported a position in Edwards Lifesciences in Q1 2019 and held it in 3 quarters.
  • Tuttle Capital Management's Edwards Lifesciences position peaked at $2.35M in Q1 2019.
  • 1,047 funds tracked by Wall St. Rank held Edwards Lifesciences as of Q2 2020.

Based on Tuttle Capital Management's 13F filing for Q2 2020, filed 11 Aug 2020.